Prevenar(TM), the only licensed pneumococcal conjugate vaccine, is now available in 88 countries around the world, with more than 180 million doses distributed.(1)
Pneumococcal disease affects both children and adults and is a leading cause of illness and death worldwide.(6) Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae and describes a group of illnesses, including invasive infections, such as bacteremia/sepsis and meningitis, as well as pneumonia and upper respiratory tract infections, including otitis media.(7) Prevenar is the first and only pneumococcal conjugate vaccine approved to help protect infants and young children against pneumococcal disease caused by the serotypes included in the vaccine.(7)
Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery,
development, manufacturing and marketing of pharmaceuticals, vaccines,
biotechnology products, nutritionals and non-prescription medicines that
improve the quality of life for people worldwide. The Company's major
divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort
Dodge Animal Health.
1) Data on file, Wyeth Pharmaceuticals Inc.
2) March 2007-WHO position paper
3) Health Protection Agency (HPA): Centre for Infections.
Cumulative weekly number of reports of invasive pneumococcal disease
Due to any of the seven serotypes present in PCV-7: children <2 years
In England and Wales by epidemiological year: July-June (2003 to
date). Cumulative Weekly Report IPD. February 2008.
4) World Health Organization. Pneumococcal co
|SOURCE Wyeth Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved